Nine Diagnostics was incorporated on March 8, 2024, as a Delaware corporation headquartered in Cambridge, Massachusetts. The company was established to advance the clinical translation of an AI-enabled multi-omic nanosensor platform, bringing together a physician-scientist, a cancer nanomedicine pioneer, and a quantum-defect nanotube engineer with a shared goal: giving clinicians a way to measure how a patient’s cancer is responding to treatment in real time.
The scientific foundation for Nine Diagnostics was established through a series of peer-reviewed studies from the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center. A 2021 study in Science Advances introduced the perception-based nanosensor approach, demonstrating that arrays of carbon nanotube sensors can generate composite molecular fingerprints from patient samples without requiring prior selection of specific target biomarkers. A 2022 study in Nature Biomedical Engineering extended this methodology to clinical validation in ovarian cancer, achieving 87% sensitivity and 98% specificity across 269 patients in the first large-cohort demonstration of a nanosensor liquid biopsy.
Nine Diagnostics was founded to address a core gap in oncology: current diagnostics can profile a tumor’s genomics or capture a metabolic snapshot from imaging, but do not provide the dynamic, functional signal needed to track whether a therapy is working as treatment proceeds. The company’s platform captures proteomic, metabolomic, and lipidomic information simultaneously, applies machine learning to identify disease-relevant patterns, and generates a multi-omic fingerprint that reflects real-time biological state without requiring prior knowledge of which specific biomarkers matter.
Nine Diagnostics is co-founded by Freddy T. Nguyen, MD, PhD, serving as Chief Executive Officer; Daniel A. Heller, PhD, serving as Chief Scientific Officer; and Mijin Kim, PhD, serving as Scientific Advisor. Freddy brings expertise in translational diagnostics, clinical measurement science, and AI-enabled medical technology development, with prior research at MIT and clinical training spanning medicine, oncology, and chemistry. Daniel heads the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center, where his team pioneered the nanosensor liquid biopsy approach and the machine perception methodology that underlies the platform. Mijin is a faculty member at the Georgia Institute of Technology, where she leads a research group focused on quantum-defect engineering of single-walled carbon nanotubes, developing the chemical functionalization and optical tuning approaches that underlie the platform’s core sensing capabilities.
The science is ready. What we are building now is the infrastructure to turn rigorous measurement science into tools that physicians can actually use to make better decisions for patients. That means clinical validation, commercial partnerships, and a regulatory pathway that takes the platform from research to real-world impact.
Freddy T. Nguyen, MD, PhD, CEO and Co-Founder, Nine Diagnostics
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.